France

France Environmental Health Policy Review Highlights Chemical Regulation Gaps And PFAS Risks

France’s environmental health policy review exposes critical gaps in chemical regulation, particularly for PFAS and pesticides. With rising health and economic costs, the report signals a shift towards stricter, more integrated regulation, requiring businesses to prepare for enhanced compliance, risk assessment and substitution obligations.

Dr Steven Brennan

3 min readAI-drafted, expert reviewed

Industrial chemical plant with storage tanks and process pipework

France’s environmental health policy is under renewed scrutiny following the publication of a parliamentary information report on 16 April 2026, which identifies major shortcomings in chemical regulation, risk assessment and policy coordination. The report warns that fragmented governance and insufficient resources are undermining the country’s ability to manage risks from substances such as PFAS, pesticides and fine particles, with significant implications for industry compliance and public health.

Fragmented Chemical Regulation And Policy Gaps

The report finds that environmental health policy in France remains “under-designed”, with regulatory frameworks for chemicals dispersed across multiple sectors and institutions. This fragmentation leads to inconsistencies, duplication and gaps in oversight, particularly under EU frameworks such as REACH, which leaves many substances insufficiently evaluated.

More than 350,000 chemicals are estimated to be on the global market, yet research and regulatory capacity lag far behind. The report highlights that risk assessments often rely heavily on industry-provided data, with limited public capacity for independent verification.

For professionals across the chemicals value chain, this signals increasing regulatory uncertainty and the likelihood of stricter future controls, especially as authorities push for more harmonised and precautionary approaches.

PFAS Regulation And Calls For Source Restrictions

PFAS chemicals emerge as a priority concern. The report describes widespread environmental contamination and significant data gaps, with only a fraction of the thousands of PFAS substances adequately studied.

Health risks linked to PFAS include cancers, thyroid disease and developmental effects. The report calls for a “universal restriction at source” and supports treating PFAS as a single class in regulatory frameworks.

This aligns with ongoing EU discussions on broad PFAS restrictions and suggests that companies using fluorinated substances should accelerate substitution strategies and supply chain audits.

Economic And Compliance Implications

The economic burden of environmental exposures is described as “colossal” yet underestimated. Air pollution alone costs tens of billions of euros annually in France, while PFAS-related costs in Europe could reach up to €1.7 trillion by 2050 under certain scenarios.

The report also highlights weak enforcement, limited inspections and insufficient sanctions, raising concerns about uneven compliance across sectors and potential competitive distortions.

Stakeholders including manufacturers, importers and downstream users may face tighter enforcement, expanded monitoring obligations and increased liability under a strengthened polluter-pays principle.

Governance Reform And “One Health” Strategy

To address systemic issues, the report recommends creating a unified “One Health” approach integrating human, animal and environmental health. It also proposes a national strategy with clearer prioritisation of risks, improved data sharing and stronger inter-ministerial coordination.

A key recommendation includes establishing a European “One Health” agency to streamline chemical risk assessment and reduce regulatory fragmentation.

Questions about this change

What does the France environmental health policy report mean for chemical regulation?

The report highlights major weaknesses in current chemical regulation, including fragmented frameworks and insufficient risk assessment. It signals likely tightening of rules, especially for high-risk substances like PFAS, and increased scrutiny on compliance, data transparency and lifecycle impacts across the supply chain.

Why are PFAS a priority in environmental health policy?

PFAS are persistent chemicals found widely in the environment and human populations. The report identifies serious health risks and limited data coverage, prompting calls for broad restrictions. This could lead to significant regulatory changes affecting manufacturing, product design and material selection.

Dr Steven Brennan

CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.

More from Dr Steven Brennan

Join 3,500+ professionals staying ahead

Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.

Free. Unsubscribe at any time.

Read by professionals at

  • Boeing
  • AstraZeneca
  • Siemens
  • PepsiCo
  • SpaceX